Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

137.16
-0.3200-0.23%
Post-market: 137.260.1000+0.07%19:44 EDT
Volume:2.35M
Turnover:324.19M
Market Cap:261.70B
PE:20.74
High:139.55
Open:139.31
Low:137.00
Close:137.48
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:0.61
T/O Rate:0.13%
Dividend:4.67
Dividend Rate:3.40%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:6.30
PE(LYR):19.18

Loading ...

Novartis: More Pain on the Way?

Dow Jones
·
Yesterday

Novartis AG Falls Friday, Underperforms Market

Dow Jones
·
Yesterday

Novartis Needs to Make Progress on Pipeline to Justify Valuation

Dow Jones
·
Sep 11

Novartis shareholder calls for board changes, Reuters reports

TIPRANKS
·
Sep 10

Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures

MT Newswires Live
·
Sep 10

Novartis India Hits Record High After Recent Acquisition, Distribution Deal

Reuters
·
Sep 10

Novartis AG Falls Wednesday, Outperforms Market

Dow Jones
·
Sep 10

Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says

MT Newswires Live
·
Sep 09

Novartis Shouldn't Rush to Cover Upcoming Patent Expirations

Dow Jones
·
Sep 09

RBC Initiates Novartis at Sector Perform With CHF120 Price Target

MT Newswires Live
·
Sep 09

Novartis's Stock Selloff Looks Overdone

Dow Jones
·
Sep 09

Novartis Faces Sales Hole in Early 2030s After Trial Setback

Dow Jones
·
Sep 09

Amgen Shares Plunge to Decade Low After Rival Drug Trial Fails, BMO Cuts Rating

Stock News
·
Sep 09

European Shares Steady as Drugmaker Rout Offsets Commodity Strength

Deep News
·
Sep 09

Asia Morning Call-Global Markets

Reuters
·
Sep 09

US Equity Markets End Lower After Houthi Attack on Saudi Arabia Energy Facilities

MT Newswires Live
·
Sep 09

Top Midday Decliners

MT Newswires Live
·
Sep 09

Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’

TIPRANKS
·
Sep 09

Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone

TIPRANKS
·
Sep 09

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Sep 09